Photo of Kateri Moore

Kateri Moore

  • ASSOCIATE PROFESSOR Developmental and Regenerative Biology
Print ProfilePrint Profile

Education

  • B.S., Kansas State University

  • D.V.M., Kansas State University

  • Post-Doctoral Research, Baylor College of Medicine

Biography

    My laboratory is studying both the basic biology and molecular mechanisms that make a hematopoietic stem cell a self-renewing stem cell that sustains our blood system throughout life. We do this by investigating these properties in model systems and by trying to convert other cell types into hematopoietic stem cells for eventual therapeutic uses. http://drb.mssm.edu/labs/lm.html

Research

Hematopoietic Stem Cells Normal and Reprogrammed

Specific Clinical/Research Interest: Stem Cells/Microenvironment/Stem Cell Niche,  Molecular regulation of hematopoietic stem cell self renewal and differentiation, molecular interaction of stem cells and microenvironmental elements. Direct differentiation of somatic cells into hematopoietic stem cells.

Current Students: Jeffrey Bernitz
Yesai Fstkchyan
Research Personnel: Xiaohong Niu
Summary of Research Studies: Primary research interest is in defining the cellular and molecular nature of the hematopoietic stem cells (HSCs) and in particular the molecular cross-talk between stem cells and their niche. Approach is to use mouse models to study HSC during normal homeostasis and after stress. Also using specific factors to directly induce HSCs from somatic cells to develop patient specific stem cells and differentiated blood products for cell replacement therapies.

Publications

Daniel MG, Pereira CF, Lemischka IR, Moore KA. Making a Hematopoietic Stem Cell. Trends in cell biology 2015 Oct;.

Pereira CF, Lemischka IR, Moore K. 'From blood to blood': de-differentiation of hematopoietic progenitors to stem cells. The EMBO journal 2014 Jun;.

Mulero-Navarro S, Sevilla A, Roman AC, Lee DF, D'Souza SL, Pardo S, Riess I, Su J, Cohen N, Schaniel C, Rodriguez NA, Baccarini A, Brown BD, Cavé H, Caye A, Strullu M, Yalcin S, Park CY, Dhandapany PS, Yongchao G, Edelmann L, Bahieg S, Raynal P, Flex E, Tartaglia M, Moore KA, Lemischka IR, Gelb BD. Myeloid Dysregulation in a Human Induced Pluripotent Stem Cell Model of PTPN11-Associated Juvenile Myelomonocytic Leukemia. Cell reports 2015 Oct; 13(3).

Adomako A, Calvo V, Biran N, Osman K, Chari A, Paton JC, Paton AW, Moore K, Schewe DM, Aguirre-Ghiso JA. Identification of markers that functionally define a quiescent multiple myeloma cell sub-population surviving bortezomib treatment. BMC cancer 2015; 15.

Pereira CF, Lemischka IR, Moore K. . Cell cycle 2014 Feb 13(3):335-336.

Qiu J, Papatsenko D, Niu X, Schaniel C, Moore K, Paton JC, Paton AW, Moore K, Schewe DM, Aguirre-Ghiso JA. Divisional History and Hematopoietic Stem Cell Function during Homeostasis. Stem cell reports 2014 Apr; 2(4).

Bernitz JM, Moore KA, Niu X, Schaniel C, Moore K. Uncovering the origins of a niche. eLife 2014 3.

Pereira CF, Chang B, Qiu J, Niu X, Papatsenko D, Hendry CE, Clark NR, Nomura-Kitabayashi A, Kovacic JC, Ma'ayan A, Schaniel C, Lemischka IR, Moore K. Induction of a hemogenic program in mouse fibroblasts. Cell stem cell 2013 Aug; 13(2).

Lee DF, Su J, Ang YS, Carvajal-Vergara X, Mulero-Navarro S, Pereira CF, Gingold J, Wang HL, Zhao R, Sevilla A, Darr H, Williamson AJ, Chang B, Niu X, Aguilo F, Flores ER, Sher YP, Hung MC, Whetton AD, Gelb BD, Moore KA, Snoeck HW, Ma'ayan A, Schaniel C, Lemischka IR. Regulation of embryonic and induced pluripotency by aurora kinase-p53 signaling. Cell stem cell 2012 Aug; 11(2).

Pereira CF, Lemischka IR, Moore K, Carvajal-Vergara X, Mulero-Navarro S, Pereira CF, Gingold J, Wang HL, Zhao R, Sevilla A, Darr H, Williamson AJ, Chang B, Niu X, Aguilo F, Flores ER, Sher YP, Hung MC, Whetton AD, Gelb BD, Moore KA, Snoeck HW, Ma'ayan A, Schaniel C, Lemischka IR. Reprogramming cell fates: insights from combinatorial approaches. Annals of the New York Academy of Sciences 2012 Aug; 1266.

Schaniel C, Sirabella D, Qiu J, Niu X, Lemischka IR, Moore KA. Wnt-inhibitory factor 1 dysregulation of the bone marrow niche exhausts hematopoietic stem cells. Blood 2011 Sep; 118: 2420-2429.

Honda H, Takubo K, Oda H, Kosaki K, Tazaki T, Yamasaki N, Miyazaki K, Moore KA, Honda Z, Suda T, Lemischka IR. Hemp, an mbt domain-containing protein, plays essential roles in hematopoietic stem cell function and skeletal formation. Proceedings of the National Academy of Sciences of the United States of America 2011 Feb; 108(6).

Glauche I, Moore K, Thielecke L, Horn K, Loeffler M, Roeder I, Miyazaki K, Moore KA, Honda Z, Suda T, Lemischka IR. Stem cell proliferation and quiescence--two sides of the same coin. PLoS computational biology 2009 Jul; 5(7).

Schaniel C, Moore KA, Thielecke L, Horn K, Loeffler M, Roeder I. Genetic models to study quiescent stem cells and their niches. Annals of the New York Academy of Sciences 2009 Sep; 1176.

Moore KA, Lemischka IR. Stem cells and their niches. Science 2006 Mar 31; 311(5769): 1880-1885.

Ivanova NB, Dimos JT, Schaniel C, Hackney JA, Moore KA, Lemischka IR. A stem cell molecular signature. Science 2002 Oct 18; 298(5593): 601-604.

Hackney JA, Charbord P, Brunk BP, Stoeckert CJ, Lemischka IR, Moore KA. A molecular profile of a hematopoietic stem cell niche. Proc Natl Acad Sci U S A 2002 Oct 1; 99(20): 13061-13066.

Phillips RL, Ernst RE, Brunk B, Ivanova N, Mahan MA, Deanehan JK, Moore KA, Overton GC, Lemischka IR. The genetic program of hematopoietic stem cells. Science 2000 Jun 2; 288(5471): 1635-1640.

Moore KA, Pytowski B, Witte L, Hicklin D, Lemischka IR, Deanehan JK, Moore KA, Overton GC, Lemischka IR. Hematopoietic activity of a stromal cell transmembrane protein containing epidermal growth factor-like repeat motifs. Proc Natl Acad Sci USA 1997 Apr 15; 94(8): 4011-4016.

Moore KA, Ema H, Lemischka IR, Hicklin D, Lemischka IR. In vitro maintenance of highly purified, transplantable hematopoietic stem cells. Blood 1997 Jun 15; 89(12): 4337-4347.

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Dr. Moore did not report having any of the following types of financial relationships with industry during 2015 and/or 2016: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.

Edit profile in Sinai Central

Address

Icahn (East) Building Floor 13 Room 20E
1425 Madison Avenue
New York, NY 10029

Tel: 212-659-8312
Fax: 212-803-6740

Address

Icahn (East) Building Room 13-26 (Lab)
1425 Madison Avenue
New York, NY 10029

Tel: 212-659-8251